scholarly journals Clinical Applications of Mesenchymal Stromal Cells (MSCs) in Orthopedic Diseases

2019 ◽  
Author(s):  
Jiazhao Yang ◽  
Shiyuan Fang ◽  
Lei Xu ◽  
Li Li ◽  
Kai Xie ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Clinical Applications ◽  
Orthopedic Diseases

Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications

Cytotherapy ◽  
2018 ◽  
Vol 20 (9) ◽  
pp. 1110-1123 ◽  
Author(s):  
MARÍA DOLORES LÓPEZ-LUCAS ◽  
GISELA PACHÓN-PEÑA ◽  
ANA MARÍA GARCÍA-HERNÁNDEZ ◽  
ANTONIO PARRADO ◽  
DARÍO SÁNCHEZ-SALINAS ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Good Manufacturing Practice ◽  
Clinical Applications ◽  
Human Mesenchymal Stromal Cells

scholarly journals Human multipotent mesenchymal stromal cells cytokine priming promotes RAB27B-regulated secretion of small extracellular vesicles with immunomodulatory cargo

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Anastasia Cheng ◽  
Dongsic Choi ◽  
Maximilien Lora ◽  
Dominique Shum-Tim ◽  
Janusz Rak ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
T Cell ◽  
Extracellular Vesicles ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Multipotent Mesenchymal Stromal Cells ◽  
Clinical Applications ◽  
T Cell Proliferation ◽  
Dependent Manner ◽  
Soluble Factors

Abstract Background The paracrine effects of multipotent mesenchymal stromal cells (MSCs) are mediated by their secretome composed by soluble factors (i.e., cytokines, growth factors, hormones) and extracellular vesicles (EVs). EVs promote intercellular communication, and the EV cargoes [e.g., proteins, soluble factors, microRNAs (miRNAs), messenger RNA (mRNA), DNA] reflect the molecular and functional characteristics of their parental cells. MSC-derived EVs (MSC-EVs) are currently evaluated as subcellular therapeutics. A key function of the MSC secretome is its ability to promote immune tolerance (i.e., immunopotency), a property that is enhanced by priming approaches (e.g., cytokines, hypoxia, chemicals) and inversely correlates with the age of the MSC donors. We evaluated mechanisms underlying MSC vesiculation and the effects of inflammation and aging on this process. Methods We evaluated the effects of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) on human adipose-derived MSC: (a) vesiculation (custom RT2 Profiler PCR Array), (b) EV profiles (Nanoparticle Tracking Analysis and Nanoparticle Flow Cytometry), (c) EV cargo (proteomic analysis and Western blot analysis), and (d) immunopotency (standard MSC:CD4 T cell proliferation inhibition assay). We confirmed the role of RAB27B on MSC vesiculation (RAB27B siRNA) and assessed its differential contribution to vesiculation in adult and pediatric MSCs (qPCR). Results Cytokine priming upregulated RAB27B in adipose-derived MSCs increasing their secretion of exosome-like small EVs (sEVs; < 200 nm) containing two key mediators of immunopotency: A20 and TSG-6. These EVs inhibited T cell proliferation in a dose-dependent manner. RAB27B siRNA inhibited MSC vesiculation. Adipose-derived MSCs isolated from pediatric donors exhibited higher RAB27B expression and secreted more sEVs than adult MSCs. Conclusions Cytokine priming is a useful strategy to harvest anti-inflammatory MSC-sEVs for clinical applications. Of relevance, donor age should be considered in the selection of MSC-sEVs for clinical applications.

New clinical applications of mesenchymal stromal cells in autoinmune diseases

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S43-S44 ◽  
Author(s):  
A. Ruiz-Garcia ◽  
J. Sabio ◽  
F. Jaen Aguila ◽  
N. Fernández ◽  
A. Ordonez-Luque ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Clinical Applications

scholarly journals Challenges and advances in clinical applications of mesenchymal stromal cells

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Tian Zhou ◽  
Zenan Yuan ◽  
Jianyu Weng ◽  
Duanqing Pei ◽  
Xin Du ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Therapeutic Potential ◽  
Clinical Applications ◽  
Disease Models ◽  
Animal Disease ◽  
Animal Disease Models

AbstractMesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.

Sign in / Sign up

Export Citation Format

Share Document